Evaluation the Toxicity, Safety, and Efficacy of Deferasirox Locally Manufactured Product in Iron Chelation of Hemoglubinopathic Patients in Iraq

Background: Thalassemia is a genetic condition that requires at least one parent to be a carrier, this condition is inherited. Certain types of blood diseases are characterized by frequent transfusions of blood, including sickle cell disease, anemia, and thalassemia. Blood transfusions offer many advantages, but they might cause the body to store too much iron. Extra iron in the body can lead to serious complications. Eliminating excess iron may reduce the risk of certain disorders. IpJade (deferasirox) is a medication used to treat chronically high iron levels in the body caused by frequent blood transfusions. Objective: The aim of the present study is to identify the safety and efficacy of deferasirox locally manufactured product in iron chelation of hemoglubinopathic patients in Iraq. Patients and Methods: This study was done at the Children’s Educational Hospital / Hemoglobinopathy center in Karbala. 100 patients’ medical records were acquired randomly who were diagnosed with B-thalassemia Major between the ages of 5 to 27. The information recorded included whether the patient was male or female, the daily dose of Deferasirox prescribed for each patient, and common side effects the patients were experiencing, as well as hepatic and renal function biomarkers. Results: The results obtained from this study showed slight changes in some biomarkers (WBC, AST, serum ferritin) while clear and strong changes in other (ALT. Alkaline phosphate, serum creatinine) before and after the treatment. The findings of this study revealed a statistically association between the serum creatinine and Deferasirox doses in addition to hepatic enzymes. Conclusion: This study revealed that the iron chelating agent (Deferasirox) is proven to be the best for patient compliance due to its favored administration compared to other types, it is shown to be well tolerated and efficacious in patients despite some negative effect which need periodic monitoring.

Authors

Institutions

Publication Details

Journal
International Journal for Scientific Research
Published
2025-05-24
DOI
https://doi.org/10.59992/ijsr.2025.v4n5p10
Citations
1
Primary Topic
Hemoglobinopathies and Related Disorders
Type
article
Field-Weighted Citation Impact
1.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation the Toxicity, Safety, and Efficacy of Deferasirox Locally Manufactured Product in Iron Chelation of Hemoglubinopathic Patients in Iraq

Iman Hussein Naser, Amal Umran Mosa, Ahmed Salih Sahib, Rejaa Umran et al.
1 citations
International Journal for Scientific Research
Hemoglobinopathies and Related Disorders
1.63
article

Evaluation the Toxicity, Safety, and Efficacy of Deferasirox Locally Manufactured Product in Iron Chelation of Hemoglubinopathic Patients in Iraq

Iman Hussein Naser, Amal Umran Mosa, Ahmed Salih Sahib, Rejaa Umran, Nabeel Arif
article en
1 citations

Abstract

Background: Thalassemia is a genetic condition that requires at least one parent to be a carrier, this condition is inherited. Certain types of blood diseases are characterized by frequent transfusions of blood, including sickle cell disease, anemia, and thalassemia. Blood transfusions offer many advantages, but they might cause the body to store too much iron. Extra iron in the body can lead to serious complications. Eliminating excess iron may reduce the risk of certain disorders. IpJade (deferasirox) is a medication used to treat chronically high iron levels in the body caused by frequent blood transfusions. Objective: The aim of the present study is to identify the safety and efficacy of deferasirox locally manufactured product in iron chelation of hemoglubinopathic patients in Iraq. Patients and Methods: This study was done at the Children’s Educational Hospital / Hemoglobinopathy center in Karbala. 100 patients’ medical records were acquired randomly who were diagnosed with B-thalassemia Major between the ages of 5 to 27. The information recorded included whether the patient was male or female, the daily dose of Deferasirox prescribed for each patient, and common side effects the patients were experiencing, as well as hepatic and renal function biomarkers. Results: The results obtained from this study showed slight changes in some biomarkers (WBC, AST, serum ferritin) while clear and strong changes in other (ALT. Alkaline phosphate, serum creatinine) before and after the treatment. The findings of this study revealed a statistically association between the serum creatinine and Deferasirox doses in addition to hepatic enzymes. Conclusion: This study revealed that the iron chelating agent (Deferasirox) is proven to be the best for patient compliance due to its favored administration compared to other types, it is shown to be well tolerated and efficacious in patients despite some negative effect which need periodic monitoring.

International Journal for Scientific ResearchVol. 4(5)
University of Kerbala (IQ)
Openalex Percentile: Top 17%
Hemoglobinopathies and Related Disorders
1.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.